We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Ultra-Fast Test Screens for All Types of Cancer with Simple Blood Draw

By LabMedica International staff writers
Posted on 29 Aug 2024

Cancer can occur at any stage of life, irrespective of age, lifestyle, or genetic background, making early detection critical for effective treatment and better patient outcomes. More...

This underscores a pressing need for improved diagnostic methods in the medical field. Current cancer detection methods face challenges such as limited availability of screening tests, lengthy result processing times, high costs, and invasive procedures. Now, a pioneering technology has been developed that facilitates the early detection of cancer, potentially as early as stage -1, and aids in guiding subsequent imaging tests.

Oncosure (Pompano Beach, FL, USA) has launched its innovative Rapid Cancer Screening Test, democratizing access to early cancer detection. This test, requiring only a single blood draw, is capable of screening for all cancer types, thereby providing reassurance to individuals. Oncosure's cutting-edge screening technology employs rapid in situ hybridization and DNA fluorescent probes to deliver comprehensive and accurate cancer screening. The technology combines a rapid SITU hybridization platform, DNA fluorescent probes for ploidy detection, and cost-effective density gradient and low sequential centrifugation methods to provide thorough screening for aneuploidy across all chromosomes.

The Oncosure test identifies oncosomes—tiny vesicles that are markers of cancer cells—across all types of cancer. Employing advanced fluorescent microscopy, the test ensures precise and actionable outcomes. It offers a swift and dependable method for detecting cancer at very early stages, even stage -1, providing results that are both fast and definitive within a few hours. This enables healthcare providers to make timely decisions. Additionally, the Oncosure test can be instrumental in monitoring the efficacy of ongoing cancer treatments and in providing early detection of cancer recurrence for those in remission, enhancing the chances for successful intervention.

"One blood draw, all cancers—this is the future of cancer screening," said Jason Andrews, Vice President of Oncosure. "Cancer doesn't wait for symptoms, and neither should you. Our test empowers everyone to screen for any type of cancer with a single, non-invasive test."

Related Links:
Oncosure


Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Online QC Software
Acusera 24•7
HPV Molecular Test
BD Onclarity HPV Assay
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A new study identifies distinct metabolomic signatures in maternal blood associated with both the timing and type of early birth (Image credit: iStock)

Maternal Blood Biomarkers Identify Risk of Preterm and Early-Term Birth

Preterm and early-term births can lead to lasting complications because vital organs continue to mature during the final weeks of pregnancy. Babies born too soon face increased risks of breathing difficulties,... Read more

Microbiology

view channel
Image: Burkholderia pseudomallei is a soil-dwelling bacterium that causes melioidosis, a severe and potentially fatal infection that remains difficult to diagnose (Image Credit: Gavin Koh/Wikimedia Commons, CC BY-SA 4.0)

Stronger Laboratory Services Support Timely Melioidosis Diagnosis Amid Global Spread

Melioidosis, a potentially fatal infection caused by Burkholderia pseudomallei, remains difficult to recognize because its symptoms can mimic tuberculosis and other illnesses. The disease is considered... Read more

Industry

view channel
Image

QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools

QIAGEN (Venlo, Netherlands) has introduced additions to its QIAcuity dPCR ecosystem that focus on gene expression, expanded assay content, and workflow standardization for life sciences and biopharma users.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.